Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00211185
Status:
COMPLETED
Last Update Posted:
2020-03-18
First Post:
2005-09-13
Brief Title:
A Study of ONTAK and CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma
Sponsor:
Eisai Inc
Organization:
Eisai Inc
Study Overview
Official Title:
A Pilot Phase II Study to Determine the Safety and Efficacy of the Combination of ONTAK With CHOP in Peripheral T-Cell Lymphoma
Status:
COMPLETED
Status Verified Date:
2020-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Study of ONTAK and CHOP chemotherapy drugs to find out their ability to make Peripheral T-cell lymphoma disappear for any period of time and potentially lengthen life The study will also compare what kind of side effects these drugs cause and how often they occur The hypothesis is that patients with newly diagnosed peripheral T-Cell lymphoma when given ONTAK CHOP will tolerate the treatment and will have a 20 improvement in response rate when compared to CHOP alone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None